Loading
Pharmacogenomic Drug Interaction / Depression Major Depressive Disorder / Comprehensive medication management with PGx testing results · Interventional Study
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned prospective randomized trial (NCT07373470) evaluating whether pharmacogenomic-guided comprehensive medication management by community pharmacists improves depression outcomes compared with usual care. No results are available; the study has not yet begun recruitment. The protocol is registered and the primary outcome is change in PHQ-8 score at 6 weeks, 12 weeks, and 6 months.
Interventional, Randomized, Parallel, Open label, Health Services Research purpose. Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services; age from 18 Years. Intervention: Comprehensive medication management with PGx testing results; Usual care. Compared with: Usual care (PGx results provided at end of study). n = 220. 1 site: United States.
This is a planned prospective randomized trial (NCT07373470) evaluating whether pharmacogenomic-guided comprehensive medication management by community pharmacists improves depression outcomes compared with usual care. No results are available; the study has not yet begun recruitment. The protocol is registered and the primary outcome is change in PHQ-8 score at 6 weeks, 12 weeks, and 6 months.
Community pharmacy setting limits generalizability to other care models.
Once complete, this trial will determine whether pharmacist-led integration of PGx results into medication management meaningfully improves depression symptom control in community pharmacy settings. Results could inform practice guidelines on the value of pharmacogenomic-guided antidepressant selection and management.
This is a trial registry record describing a planned randomized study with no results yet posted; enrollment has not begun.
As stated by the source record.
Quoted from the source exactly as published.
Once complete, this trial will determine whether pharmacist-led integration of PGx results into medication management meaningfully improves depression symptom control in community pharmacy settings. Results could inform practice guidelines on the value of pharmacogenomic-guided antidepressant selection and management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07373470). This is a study registration, not published results. Lead sponsor: University of Pittsburgh. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 220 participants (ESTIMATED). Conditions: Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services. Interventions: OTHER: Comprehensive medication management with PGx testing results; OTHER: Usual Care. Primary outcome measures: Change in Patient Health Questionnaire (PHQ-8) score , Baseline, 6 Weeks, 12 Weeks, 6 Months. Brief summary: The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes. The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care. Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.